‘A Momentous, Critical Step’: Paradigm Shift Ahead For US Biosimilars As FDA Formalizes Streamlining

Removal Of Comparative Efficacy Study Requirement Wins Plaudits

 
• By Dave Wallace
  
The FDA has committed to a streamlined biosimilars pathway (Shutterstock)

More from Biosimilars

More from Products